LexaGene Honored as a Top 50-Ranked TSX Venture Company
TSX Venture 50 Ranks the Strongest Companies on TSX Venture Exchange by Share Price, Trading Volume and Market Capitalization
BEVERLY, Mass., February 22, 2018 – LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that the TSX Venture Exchange has ranked the Company in its 2018 TSX Venture 50, an annual ranking of top performing companies on the Exchange.
“Being recognized as a top 50 company for the Exchange reflects the rapid growth we’ve experienced in 2017 and great support from the investment community,” said Dr. Jack Regan, LexaGene’s CEO. “Following our recent completion of the assembly of our prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform, LexaGene is poised to make a powerful impact for industries interested in pathogen detection – from food safety to veterinary diagnostics.”
Each year, the ranking showcases TSX-V-listed companies that have shown notable results in key measures of market performance. The companies included in the 2018 TSX Venture 50 were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. To learn more about LexaGene and the TSX Venture 50, please click here.
To be added to the LexaGene email distribution list, please subscribe on the LexaGene website here.
About LexaGene Holdings Inc.
LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access, the LX6. The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection. The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour. The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.